- $3.38bn
- $5.39bn
- $1.10bn
- 86
- 32
- 75
- 70
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.82 | ||
| PEG Ratio (f) | 0.45 | ||
| EPS Growth (f) | 49.43% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.15 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 31.87 | ||
| Price to Sales | 3.05 | ||
| EV to EBITDA | 13.13 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.58% | ||
| Return on Equity | 5.88% | ||
| Operating Margin | 22.26% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 818.16 | 931.48 | 1,003.69 | 1,049.29 | 1,100.44 | 1,141.43 | 1,208.78 | 7.17% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +799.34 | +592.13 | -42.88 | +16.45 | -19.72 | +147.3 | +13.77 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company’s segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.
Directors
- Michael Petras CHM
- Scott Leffler CFO (45)
- Michael Rutz CEX (49)
- Matthew Klaben SVP (51)
- Ruoxi Chen IND (37)
- Sean Cunningham IND (45)
- David Donnini IND (55)
- Stephanie Geveda IND (41)
- Ann Klee IND (59)
- Constantine Mihas IND (54)
- James Neary IND (56)
- Vincent Petrella IND (60)
- David Wheadon IND (63)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- March 18th, 2015
- Public Since
- November 20th, 2020
- No. of Shareholders
- 77
- No. of Employees
- 3,000
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 283,855,074
- Address
- 9100 South Hills Blvd, BROADVIEW HEIGHTS, 44147
- Web
- https://soterahealth.com/
- Phone
- +1 4402621410
- Contact
- Jason Peterson
- Auditors
- Ernst & Young LLP
Latest News for SHC
Upcoming Events for SHC
Q2 2025 Sotera Health Co Earnings Release
Q3 2025 Sotera Health Co Earnings Release
Similar to SHC
Acadia Healthcare
NASDAQ Global Select Market
Addus HomeCare
NASDAQ Global Select Market
Alignment Healthcare
NASDAQ Global Select Market
Amedisys
NASDAQ Global Select Market
Aveanna Healthcare Holdings
NASDAQ Global Select Market
FAQ
As of Today at 05:21 UTC, shares in Sotera Health Co are trading at $11.89. This share price information is delayed by 15 minutes.
Shares in Sotera Health Co last closed at $11.89 and the price had moved by +1.8% over the past 365 days. In terms of relative price strength the Sotera Health Co share price has underperformed the S&P500 Index by -9.48% over the past year.
The overall consensus recommendation for Sotera Health Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreSotera Health Co does not currently pay a dividend.
Sotera Health Co does not currently pay a dividend.
Sotera Health Co does not currently pay a dividend.
To buy shares in Sotera Health Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $11.89, shares in Sotera Health Co had a market capitalisation of $3.38bn.
Here are the trading details for Sotera Health Co:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SHC
Based on an overall assessment of its quality, value and momentum Sotera Health Co is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Sotera Health Co is $14.50. That is 21.95% above the last closing price of $11.89.
Analysts covering Sotera Health Co currently have a consensus Earnings Per Share (EPS) forecast of $0.75 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sotera Health Co. Over the past six months, its share price has underperformed the S&P500 Index by -15.72%.
As of the last closing price of $11.89, shares in Sotera Health Co were trading -9.38% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sotera Health Co PE ratio based on its reported earnings over the past 12 months is 14.82. The shares last closed at $11.89.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sotera Health Co's management team is headed by:
- Michael Petras - CHM
- Scott Leffler - CFO
- Michael Rutz - CEX
- Matthew Klaben - SVP
- Ruoxi Chen - IND
- Sean Cunningham - IND
- David Donnini - IND
- Stephanie Geveda - IND
- Ann Klee - IND
- Constantine Mihas - IND
- James Neary - IND
- Vincent Petrella - IND
- David Wheadon - IND